Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a mid-stage trial. The results also put a dampener on the ...
August 26, 2026 07:00 AM EDT R&D Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data Ayisha Sharma News Reporter Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that